207 related articles for article (PubMed ID: 26165597)
21. KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation.
Tran TH; Chan AH; Young LC; Bindu L; Neale C; Messing S; Dharmaiah S; Taylor T; Denson JP; Esposito D; Nissley DV; Stephen AG; McCormick F; Simanshu DK
Nat Commun; 2021 Feb; 12(1):1176. PubMed ID: 33608534
[TBL] [Abstract][Full Text] [Related]
22. Assignments of backbone ¹H, ¹³C and ¹⁵N resonances in H-Ras (1-166) complexed with GppNHp at physiological pH.
O'Connor C; Kovrigin EL
Biomol NMR Assign; 2012 Apr; 6(1):91-3. PubMed ID: 21814767
[TBL] [Abstract][Full Text] [Related]
23. Computed three-dimensional structures for the ras-binding domain of the raf-p74 protein complexed with ras-p21 and with its suppressor protein, rap-1A.
Chen JM; Manolatos S; Brandt-Rauf PW; Murphy RB; Monaco R; Pincus MR
J Protein Chem; 1996 Aug; 15(6):511-8. PubMed ID: 8895097
[TBL] [Abstract][Full Text] [Related]
24. Molecular interaction between K-Ras and H-REV107 in the Ras signaling pathway.
Han CW; Jeong MS; Jang SB
Biochem Biophys Res Commun; 2017 Sep; 491(2):257-264. PubMed ID: 28743497
[TBL] [Abstract][Full Text] [Related]
25. Cryo-EM structure of a RAS/RAF recruitment complex.
Park E; Rawson S; Schmoker A; Kim BW; Oh S; Song K; Jeon H; Eck MJ
Nat Commun; 2023 Jul; 14(1):4580. PubMed ID: 37516774
[TBL] [Abstract][Full Text] [Related]
26. Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.
Verkhivker GM
Mol Biosyst; 2016 Oct; 12(10):3146-65. PubMed ID: 27481329
[TBL] [Abstract][Full Text] [Related]
27. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
Kordes M; Röring M; Heining C; Braun S; Hutter B; Richter D; Geörg C; Scholl C; Gröschel S; Roth W; Rosenwald A; Geissinger E; von Kalle C; Jäger D; Brors B; Weichert W; Grüllich C; Glimm H; Brummer T; Fröhling S
Leukemia; 2016 Apr; 30(4):937-46. PubMed ID: 26582644
[TBL] [Abstract][Full Text] [Related]
28. Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets.
Moodie SA; Paris M; Villafranca E; Kirshmeier P; Willumsen BM; Wolfman A
Oncogene; 1995 Aug; 11(3):447-54. PubMed ID: 7630628
[TBL] [Abstract][Full Text] [Related]
29. Nuclear magnetic resonance and molecular dynamics studies on the interactions of the Ras-binding domain of Raf-1 with wild-type and mutant Ras proteins.
Terada T; Ito Y; Shirouzu M; Tateno M; Hashimoto K; Kigawa T; Ebisuzaki T; Takio K; Shibata T; Yokoyama S; Smith BO; Laue ED; Cooper JA
J Mol Biol; 1999 Feb; 286(1):219-32. PubMed ID: 9931261
[TBL] [Abstract][Full Text] [Related]
30. Molecular dynamics on complexes of ras-p21 and its inhibitor protein, rap-1A, bound to the ras-binding domain of the raf-p74 protein: identification of effector domains in the raf protein.
Chen JM; Monaco R; Manolatos S; Brandt-Rauf PW; Friedman FK; Pincus MR
J Protein Chem; 1997 Aug; 16(6):619-29. PubMed ID: 9263124
[TBL] [Abstract][Full Text] [Related]
31. Regional polysterism in the GTP-bound form of the human c-Ha-Ras protein.
Ito Y; Yamasaki K; Iwahara J; Terada T; Kamiya A; Shirouzu M; Muto Y; Kawai G; Yokoyama S; Laue ED; Wälchli M; Shibata T; Nishimura S; Miyazawa T
Biochemistry; 1997 Jul; 36(30):9109-19. PubMed ID: 9230043
[TBL] [Abstract][Full Text] [Related]
32. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
33. Solution structure and backbone dynamics of the TGFbeta type II receptor extracellular domain.
Deep S; Walker KP; Shu Z; Hinck AP
Biochemistry; 2003 Sep; 42(34):10126-39. PubMed ID: 12939140
[TBL] [Abstract][Full Text] [Related]
34. Development of new anti-cancer peptides from conformational energy analysis of the oncogenic ras-p21 protein and its complexes with target proteins.
Pincus MR
Front Biosci; 2004 Sep; 9():3486-509. PubMed ID: 15353372
[TBL] [Abstract][Full Text] [Related]
35. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
36. Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane.
Fang Z; Lee KY; Huo KG; Gasmi-Seabrook G; Zheng L; Moghal N; Tsao MS; Ikura M; Marshall CB
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12101-12108. PubMed ID: 32414921
[TBL] [Abstract][Full Text] [Related]
37. Dynamic properties of the Ras switch I region and its importance for binding to effectors.
Spoerner M; Herrmann C; Vetter IR; Kalbitzer HR; Wittinghofer A
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4944-9. PubMed ID: 11320243
[TBL] [Abstract][Full Text] [Related]
38. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation.
Thevakumaran N; Lavoie H; Critton DA; Tebben A; Marinier A; Sicheri F; Therrien M
Nat Struct Mol Biol; 2015 Jan; 22(1):37-43. PubMed ID: 25437913
[TBL] [Abstract][Full Text] [Related]
39. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
40. Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
Di Michele M; Stes E; Vandermarliere E; Arora R; Astorga-Wells J; Vandenbussche J; van Heerde E; Zubarev R; Bonnet P; Linders JT; Jacoby E; Brehmer D; Martens L; Gevaert K
J Proteome Res; 2015 Oct; 14(10):4179-93. PubMed ID: 26293246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
